Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) climbed 9.41% to $45.36 in the morning hour after the company provided full year financial guidance for 2012 reflecting the planned business combination with Azur Pharma Public Limited Company, which the companies are targeting to close during the week of January 16, 2012. The company also announced that the Hart-Scott-Rodino waiting period has expired.
Barnes & Noble, Inc. (NYSE: BKS) gained 4.54% to $11.75 in the morning hour after the company said it is looking at options to spin off the popular e-book reader Nook as a separate business unit. By fiscal 2012 year-end, based upon forecasted device sales, the company expects annualized U.S. digital content sales will achieve a run-rate of approximately $700 [million to] $750 million.
MannKind Corporation (NASDAQ: MNKD) climbed 9.62% to $2.62 in the early hour after the company announced that it will present at the 30th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2012 at 8:00 am (PT) at the Westin St. Francis Hotel in San Francisco, California.
Spreadtrum Communications, Inc (ADR) (NASDAQ: SPRD) plunged 11.99% to $16.95 in the morning hour. On January 04, 2012, the company introduced a 1GHz Android smartphone platforms for TD-SCDMA (SC8810) and EDGE/WiFi (SC6820) and announced that both products are now sampling with customers. With these two new solutions, Spreadtrum is redefining the performance standard for low-cost smartphones, enabling OEMs to deliver 1GHz performance at US$100 retail prices.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.